Risk factor
Good trading liquidity
Profitability factor
Greatly overvalued vs peers
About
Zhejiang Hisoar Pharmaceutical Co., Ltd. is a pharmaceutical enterprise that specializes in the manufacturing and global distribution of fine chemicals and specialized active pharmaceutical ingredients (APIs). Its diverse product portfolio encompasses materials used in the production of antibiotics, antiviral medications, cardiovascular drugs, and glucose-reducing agents, among others. Beyond these core APIs, the company also supplies pharmaceutical intermediates and provides customized processing services. Key products include clindamycin, the 4-AA Iso-carbapenem series, thiamphenicol, florfenicol, and voglibose. A significant portion of its output is destined for international markets through exports. Established in 1966, the company maintains its operational headquarters in Taizhou, China.
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. Specifically, the stock is overvalued on EV/EBITDA.